[1] Haynes WG, Ferro C J, O’Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans[J]. Circulation, 1996, 93 (10):1860-70. [2] Ihling C, Bohrmann B, Schaefer HE, et al. Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis-novel targets for pharmacotherapy in atherosclerosis [J]. Curr Vasc Pharmacol, 2004,2(3):249-58. [3] Kelly DP. The pleiotropic nature of the vascular PPAR gene regulatory pathway[J]. Circ Res, 2001, 89( 11 ):935-7. [4] Verreth W, De Keyzer D, Pelat M, et al. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice [J]. Circulation, 2004, 110(20):3259-69. [5] Marx N, DuezH, FruchartJC, et al. Peroxisome proliferatoractivated receptors and atherogenesis:regulators of gene expression in vascular cells[J]. Circ Res, 2004, 94(9):1168-78 [6] Castrillo A, Tontonoz P. PPARs in atherosclerosis:the clot thickens [J].J Clin Invest, 2004, 114(11):1538-40. [7] Iglarz M, Touyz RM, Amiri F, et al. Effect ofperoxisome proliferatoractivated receptor-alpha and-gamma activators on vascular remodeling in endothelin-dependent hypertension [J]. Arterioscler Thromb Vasc Biol, 2003, 23(1):45-51. [8] Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis:new perspectives and therapeutic strategies [J].Nat Med, 2002, 8(11):1249-56. [9] Merkus D, Duncker DJ, Chilian WM. Metabolic regulation of coronary vascular tone:role ofendothelin-1 [J]. Am J Physiol Heart Cire Physiol, 2002, 283(5):1915-192. [10] Olte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma [J]. Nature, 1998, 395(6698):137-43. [11] Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling [J]. Am J Physiol Heart Circ Physiol, 2005,288(3):H1037-43. [12] Hasdai D, Holmes DR Jr, Garratt KN, et al. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo[J]. Circulation, 1997, 95(2):357-62. [13] Shichiri M, Yokokura M, Marumo F, et al. Endothelin-linhibits apoptosis of vascular smooth muscle cells induced by nitric oxide and serum deprivation via MAP kinase pathway [J]. Arterioscler Thromb Vasc, 2000, 20(4):989-97. [14] Hinterhuber L, Graziadei IW, Kahler CM, et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension [J]. Clin Gastroenterol Hepatol, 2004, 2(11):1039-42. [15] Berger J, Moller DE. The mechanisms of action of PPARs [J].Annu Rev Med, 2002, 339:953-95. [16] Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferatoractivated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway [J]. Circ Res, 1999, 85(5):394-402. [17] WakinoS, KintscherU, Kim S, et al. Peroxisome proliferatoractivated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 S transition in vascular smooth muscle cells [J].J Biol Chem, 275(29):435-41. [18] Kintscher U, Lyon C J, Law RE. Angiotensin Ⅱ, PPAR-gamma and atherosclerosis[J]. Front Biosci, 2004, 9:359-69. [19] Mauricio J. Reginato, Samuel L, et al. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor[J].J Biol, 273(4), 1855-8. [20] Liu JJ, Huang RW, Lin DJ, et al. Angiotensin Ⅱ and endothelin-1regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells [J].J Hypertens, 2004, 22(6):1141-9. |